Cure SMA Releases Its 2017 SMA Drug Pipeline

Wendy Henderson avatar

by Wendy Henderson |

Share this article:

Share article via email

As more and more people affected by SMA gain access to the recently approved Spinraza therapy, Cure SMA has released its pipeline that looks at how research is going in other areas that may benefit the spinal muscular atrophy (SMA) community.

MORE: “Life and Atrophy”: A documentary about a young boy’s journey with Spinraza

According to the organization, there are currently 19 SMA therapies in clinical trials, and two of them are nearing the end of their phase II trials — AVXS-101 and Olesoxime. Cure SMA’s research program is working with 14 different pharmaceutical companies to develop better gene therapies and drug treatments to help improve the lives of those living with the disease.

Cure SMA is funding research into two main areas: SMN-based or SMN-enhancing therapies which aim to boost the body’s ability to produce survival motor neurons (SMN) and non-SMN therapies which look to improve the function of muscles and nerves.

MORE: Caring for a child with SMA when they have a cold

SMA News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.